About POU domain, class 3, transcription factor 1
POU domain, class 3, transcription factor 1 (POU3F1) is a protein
from Homo sapiens identified by UniProt accession
Q03052, 451 residues long.
MolForge cross-references it against 0 known binders and
82 disease associations.
Target properties
| Protein name | POU domain, class 3, transcription factor 1 |
| UniProt accession | Q03052 |
| Gene | POU3F1 |
| Organism | Homo sapiens |
| Length | 451 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (82)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- rheumatoid arthritis · score 0.39
- hypothyroidism · score 0.33
- serum non-albumin protein measurement · score 0.28
- thyroid disease · score 0.27
- Thyroid preparation use measurement · score 0.26
- bone density · score 0.26
- urate measurement · score 0.26
- smoking status measurement · score 0.25
- age at menarche · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q03052-F1 | alphafold | PREDICTED | 58.47 | — |
Amino-acid sequence (451 residues)
MATTAQYLPR GPGGGAGGTG PLMHPDAAAA AAAAAAAERL HAGAAYREVQ KLMHHEWLGA GAGHPVGLAH PQWLPTGGGG GGDWAGGPHL EHGKAGGGGT GRADDGGGGG GFHARLVHQG AAHAGAAWAQ GSTAHHLGPA MSPSPGASGG HQPQPLGLYA QAAYPGGGGG GLAGMLAAGG GGAGPGLHHA LHEDGHEAQL EPSPPPHLGA HGHAHGHAHA GGLHAAAAHL HPGAGGGGSS VGEHSDEDAP SSDDLEQFAK QFKQRRIKLG FTQADVGLAL GTLYGNVFSQ TTICRFEALQ LSFKNMCKLK PLLNKWLEET DSSSGSPTNL DKIAAQGRKR KKRTSIEVGV KGALESHFLK CPKPSAHEIT GLADSLQLEK EVVRVWFCNR RQKEKRMTPA AGAGHPPMDD VYAPGELGPG GGGASPPSAP PPPPPAALHH HHHHTLPGSV Q
Explore POU domain, class 3, transcription factor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets